Abstract:

Various interventions, including innovative technologies, have been used to solve problems. Over the years, the Nigerian government has introduced a good healthcare delivery system, including providing quality, efficacious and affordable drugs. The study used a qualitative design method adopting a focus group discussion approach. The selected states for the study are Lagos, Kano, Anambra and FCT Abuja. The study population comprised NAFDAC stakeholders who are dealers in pharmaceutical products or Marketing Authorization Holders (MAHs) of medicines, Consumers and Policymakers. The focus group participants were selected based on convenience sampling. The interventions highlighted were Mobile Authentication Services (MAS), on-the-spot checks on drugs through a TruScan, Black-Eye and Radio Frequency Identification Devices (RFID). The respondents also highlighted using NAFDAC registration numbers and holograms as important ways of checking the features of medicine before using it. The participants also highlighted the lack of public awareness about these interventions and the need for proper regulation and enforcement of laws against the sale and distribution of fake drugs as challenges that hinder the successful development and implementation of interventions against fake and counterfeit drugs. The participants suggested KYC measures to address issues within the supply chain to evaluate the effectiveness of their current strategies. Regular meetings, advocacy efforts, and educational workshops are recommended to raise awareness and educate stakeholders about their roles and responsibilities in pursuit of addressing the challenges related to counterfeit drug interventions.

References:

[1] Buowari, O. V. (2012). Fake and Counterfeit Drug: A review. AFRIMEDIC Journal, 3(2), 1–4. http://www.ajol.info/index.php/afrij/article/view/86573.

[2] Akunyili D., (2007). Counterfeit medicines: A serious crime against humanity. Proceedings of the Director General of the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria, to the European Parliament in Brussels. 1–7.

[3] Amadi, L., & Amadi2, M. (2014a). Sustainable Drug Consumption, Regulatory Dynamics and Fake Drug Repositioning in Nigeria: A Case of NAFDAC. Journal of Scientific Issues, 2(9), 412–419. http://www.sci-afric.org.

[4] Adelusi A J (2000) Drug Distribution: Challenges and Effects on The Nigerian Society. Keynote address at the &3rd Annual National Conference of the Pharmaceutical Society of Nigeria held at Nicon Hilton Hotel, Abuja ,6th -10th, November 2000.

[5] Akinyandenu O (2013) Counterfeit drugs in Nigeria: A threat to public health. African Journal of Pharmacy and Pharmacology. Vol. 7(36), pp. 2571-2576.

[6] Reggi, V. (2007). Counterfeit medicines: An intent to deceive. International Journal of Risk & Safety in Medicine, 19(1/2), 105–108. http://search.ebscohost.com/login.aspx?direct=true&db=a9h&AN=25215283&site=ehost-live.

[7] Ubajaka, C. F., Obi-okaro, A. C., Emelumadu, O. F., Azumarah, M. N., Ukegbu, A. U., & Ilikannu, S. O. (2016). Factors Associated with Drug Counterfeit in Nigeria : A Twelve Year Review. 12(4), 1–8. https://doi.org/10.9734/BJMMR/2016/21342.

[8] Akunyili, D. (2010). The challenges faced by NAFDAC in the National regulatory process relate to essential drugs for preventing maternal and newborn deaths in Nigeria. Tropical Journal of Obstetrics and Gynaecology, 27(April 2010).

[9] NAFDAC. (2017). NAFDAC Anti-counterfeiting Strategies. https://www.nafdac.gov.ng/about-nafdac/nafdac-anti-counterfeiting-strategies/.

[10] Horalek, J. & Sobeslav, V (2017). Track & Trace System with Serialization Prototyping Methodology for Pharmaceutical Industry in EU. 14th International Conference, https://link.springer.com/chapter/10.1007/978-3-319-65515-4_15.

[11] Egwu, P. E. (2018). Audience exposure and attitude towards NAFDAC’S ‘Mobile Authentication Service’ (MAS) campaigns in three selected southeast states. In Energies (Vol. 6, Issue 1). https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjFkJvyhujAhWTM8AKHc7iB5oQFnoECBcQAQ&url=http%3A%2F%2Frepository.unn.edu.ng%2Fbitstream%2Fhandle%2F123456789%2F9142%2FEgwu%2C%2520Patrick%2520Ejike%2520Jnr.pdf%3Fsequ.

[12] Akinyandenu, O. (2013). Counterfeit drugs in Nigeria: A threat to public health. African Journal of Pharmacy and Pharmacology, 7(36), 2571–2576. https://doi.org/10.5897/ajpp12.343.

[13] Chinedu-Okeke, C. F., Okoro, N., & Obi, I. (2021). Mobile Authentication Service (MAS) Scheme and Public Participation in Eradicating Fake Drugs in Southeast Nigeria. International Journal of Research and Innovation in Social Science, 05(06), 90–98. https://doi.org/10.47772/ijriss.2021.5605.

[14] Elizabeth Uzochukwu, C. (2017). Audience awareness and use of mobile authentication service (MAS) in identifying fake and substandard drugs in Nigeria. Journal of African Studies. Journal of African Studies, 77(11), 46–66.

[15] NAFDAC. (2010). The National Agency for Food and Drug Administration and Control (NAFDAC) Mobile Authentication Service Scheme Guidelines for the Procurement and Management of the NAFDAC Mobile Authentication Service (MAS) Scheme. NAFDAC’s MAS Implementation Guide.

[16] Adekoya, H. O., & Ekeh, C. M. (2021). Awareness and Adoption of Drug Mobile Authentication Service : A Conscious Approach in Eradication of Fake and Counterfeit Drugs in Nigeria. 7(1), 43–51.

[17] Chen, Y., Wang, Y., Wang, N., Xiang, Y., Zhang, R., Xiao, J., Liu, H., & Feng, B. (2021). A cross-sectional study of knowledge, attitude, and practice regarding pharmacovigilance among the general public in Western China. Current Medical Research and Opinion, 37(1), 101–108. https://doi.org/10.1080/03007995.2020.1846171.

[18] Mhando, L., Jande, M. B., Liwa, A., Mwita, S., & Marwa, K. J. (2016). Public Awareness and Identification of Counterfeit Drugs in Tanzania: A View on Antimalarial Drugs. Advances in Public Health, 2016, 1–8. https://doi.org/10.1155/2016/6254157.

[19] Adisa, R., Adeniyi, O. R., & Fakeye, T. O. (2019). Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria. International Journal of Clinical Pharmacy, 41(4), 1062–1073. https://doi.org/10.1007/s11096-019-00849-9.

[20] Adigwe, O. P., Onavbavba, G., & Wilson, D. O. (2022). Challenges Associated with Addressing Counterfeit Medicines in Nigeria: An Exploration of Pharmacists’ Knowledge, Practices, and Perceptions. Integrated Pharmacy Research and Practice, Volume 11(November), 177–186. https://doi.org/10.2147/iprp.s387354.

[21] Bansal, D., Malla, S., Gudala, K., & Tiwari, P. (2013). Anti-counterfeit technologies: A pharmaceutical industry perspective. Scientia Pharmaceutica, 81(1), 1–13. https://doi.org/10.3797/scipharm.1202-03.